MCID: SML016
MIFTS: 52

Small Intestine Cancer

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Small Intestine Cancer

MalaCards integrated aliases for Small Intestine Cancer:

Name: Small Intestine Cancer 12 49 14
Neoplasm of Small Intestine 12 69
Small Intestine Neoplasm 12 14
Malignant Neoplasms of the Small Intestine 49
Malignant Tumor of Small Intestine 69
Neoplasm of the Small Intestine 28
Small Intestinal Neoplasm 12
Small Intestine Carcinoma 69
Small Bowel Tumors 49

Classifications:



Summaries for Small Intestine Cancer

Disease Ontology : 12 An intestinal cancer that is located in the small intestine.

MalaCards based summary : Small Intestine Cancer, also known as neoplasm of small intestine, is related to small intestinal adenocarcinoma and gallbladder cancer. An important gene associated with Small Intestine Cancer is SST (Somatostatin), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include the small intestine, small intestine and liver, and related phenotypes are Synthetic lethal with vaccinia virus (VACV) infection and cellular

Wikipedia : 72 In oncology, small intestine cancer, also small bowel cancer and cancer of the small bowel, is a cancer... more...

Related Diseases for Small Intestine Cancer

Diseases in the Small Intestine Cancer family:

Intestine Carcinoma in Situ

Diseases related to Small Intestine Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 small intestinal adenocarcinoma 31.3 CDX2 KRAS MUC2 MUC6
2 gallbladder cancer 30.7 CCND1 KRAS MLH1 MUC2
3 duodenum cancer 30.1 CDX2 ENO2 KRAS KRT7 MUC2 MUC6
4 intestinal benign neoplasm 27.9 CCND1 CDX2 KRAS MLH1 MSH2 MUC2
5 small intestine cancer, childhood 12.1
6 small intestine carcinoid neuroendocrine tumor 10.8
7 ileum cancer 10.8
8 pancreatic intraductal papillary-mucinous neoplasm 10.5 MUC2 MUC6
9 tumor of exocrine pancreas 10.5 MUC2 MUC6
10 periampullary adenoma 10.5 KRAS SST
11 adenoma of the pancreas 10.5 KRT20 SST
12 cystic basal cell carcinoma 10.5 KRT20 KRT7
13 chronic ethmoiditis 10.5 MUC2 MUC6
14 lung acinar adenocarcinoma 10.5 KRT20 KRT7
15 seminal vesicle adenocarcinoma 10.5 KRT20 KRT7
16 bile duct mucoepidermoid carcinoma 10.5 KRT7 MUC2
17 endocervical carcinoma 10.5 KRT7 MUC6
18 transverse colon cancer 10.5 KRT20 KRT7
19 ovarian large-cell neuroendocrine carcinoma 10.5 KRT20 KRT7
20 eyelid neoplasm 10.5 KRT20 KRT7
21 small intestine leiomyosarcoma 10.5
22 squamous cell carcinoma of the small intestine 10.5
23 malignant syringoma 10.5 KRT20 KRT7
24 krukenberg carcinoma 10.5 KRT20 KRT7
25 pancreatic somatostatinoma 10.5 ENO2 SST
26 large intestine adenocarcinoma 10.5 KRT20 KRT7
27 retroperitoneal neuroblastoma 10.5 ENO2 SST
28 linitis plastica 10.5 KRT20 KRT7
29 sensory organ benign neoplasm 10.4 ENO2 KRT7
30 adenoid squamous cell carcinoma 10.4 KRT20 KRT7
31 middle ear adenoma 10.4 ENO2 KRT7
32 duodenal somatostatinoma 10.4 ENO2 SST
33 eccrine sweat gland neoplasm 10.4 KRT20 KRT7
34 vulval paget's disease 10.4 KRT20 KRT7
35 microcystic adenoma 10.4 ENO2 MUC6
36 encapsulated thymoma 10.4 CD79A SST
37 intratubular embryonal carcinoma 10.4 KRT20 KRT7
38 meibomian cyst 10.4 KRT20 KRT7
39 bladder lymphoma 10.4 KRT20 KRT7
40 mature teratoma of the ovary 10.4 ENO2 KRT20
41 papillary serous adenocarcinoma 10.4 KRT20 KRT7
42 breast adenomyoepithelioma 10.4 ENO2 KRT7
43 renal pelvis carcinoma 10.4 KRT20 KRT7
44 breast myoepithelial neoplasm 10.4 ENO2 KRT7
45 goblet cell carcinoid 10.4 ENO2 KRT20
46 medulloepithelioma 10.4 KRT20 KRT7
47 glycogen-rich clear cell breast carcinoma 10.3 KRT20 KRT7
48 mucinous tubular and spindle renal cell carcinoma 10.3 KRT7 MUC2 MUC6
49 respiratory system benign neoplasm 10.3 ENO2 KRAS
50 paget disease, extramammary 10.3 KRT20 KRT7

Comorbidity relations with Small Intestine Cancer via Phenotypic Disease Network (PDN):


Colorectal Cancer Deficiency Anemia
Intestinal Obstruction

Graphical network of the top 20 diseases related to Small Intestine Cancer:



Diseases related to Small Intestine Cancer

Symptoms & Phenotypes for Small Intestine Cancer

GenomeRNAi Phenotypes related to Small Intestine Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.02 KRAS MLH1 MSH6 CD79A CDX2

MGI Mouse Phenotypes related to Small Intestine Cancer:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.96 CD79A CDX2 ENO2 KRAS KRT7 MLH1
2 digestive/alimentary MP:0005381 9.7 CCND1 MUC2 SST CDX2 KRAS MLH1
3 homeostasis/metabolism MP:0005376 9.65 CCND1 MUC2 SST CD79A CDX2 KRAS
4 neoplasm MP:0002006 9.23 CD79A CDX2 KRAS MLH1 MSH2 MSH6

Drugs & Therapeutics for Small Intestine Cancer

Drugs for Small Intestine Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 220)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
3 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
4
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
5
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
6
Ondansetron Approved Phase 3 99614-02-5 4595
7
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
8
Ofloxacin Approved Phase 3 82419-36-1 4583
9
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
10
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
11
Morphine Approved, Investigational Phase 3 57-27-2 5288826
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
14 Orange Approved, Nutraceutical Phase 3
15 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
16 Amoxicillin-Potassium Clavulanate Combination Phase 3
17 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 3,Phase 2,Phase 1
20 Antitubercular Agents Phase 3
21 beta-Lactamase Inhibitors Phase 3
22 Clavulanic Acid Phase 3
23 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
24 Cytochrome P-450 Enzyme Inhibitors Phase 3
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
26 Dermatologic Agents Phase 3,Phase 2,Phase 1
27 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
29 glucocorticoids Phase 3,Phase 2,Phase 1
30 Hormone Antagonists Phase 3,Phase 2,Phase 1
31 Hormones Phase 3,Phase 2,Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
33 Antirheumatic Agents Phase 2, Phase 3,Phase 1
34 Anti-Anxiety Agents Phase 3
35 Antiemetics Phase 3,Phase 1
36 Antipruritics Phase 3
37 Antipsychotic Agents Phase 3
38 Autonomic Agents Phase 3,Phase 1
39 Central Nervous System Depressants Phase 3,Phase 1
40 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
41 Neurotransmitter Agents Phase 3,Phase 2,Phase 1
42 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
43 Psychotropic Drugs Phase 3
44
Serotonin Phase 3,Phase 2 50-67-9 5202
45 Serotonin Agents Phase 3,Phase 2
46 Serotonin Antagonists Phase 3,Phase 2
47 Tranquilizing Agents Phase 3
48 Epoetin alfa Phase 3 113427-24-0
49 Hematinics Phase 3
50 Renal Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 116)

# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Differences in Preparation for Small Bowel Capsule Endoscopy Recruiting NCT03351972 Phase 4 Klean Prep
3 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
4 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
5 Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy Completed NCT00003600 Phase 3
6 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
7 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
10 Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis Withdrawn NCT00026468 Phase 2, Phase 3 exisulind
11 High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
12 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
13 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
14 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
15 Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
16 Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma Completed NCT00006039 Phase 2
17 Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
18 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
19 Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas Completed NCT00005874 Phase 2 rubitecan
20 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
21 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
22 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
23 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
24 Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Completed NCT00004895 Phase 2 octreotide acetate
25 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
26 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
27 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
28 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
29 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
30 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
31 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
32 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
33 Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2 Capecitabine;Oxaliplatin
34 NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) Completed NCT00248404 Phase 1, Phase 2 NB1011
35 Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Recruiting NCT02949219 Phase 2
36 Effects of S-1 and Capecitabine on Coronary Artery Blood Flow Recruiting NCT02216149 Phase 2 S-1;Capecitabine
37 Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment Active, not recruiting NCT00416351 Phase 1, Phase 2 clofarabine
38 CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Active, not recruiting NCT01202409 Phase 2 Panitumumab
39 Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Active, not recruiting NCT01208103 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
40 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
41 Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine Terminated NCT00003522 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
42 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Terminated NCT00903396 Phase 2 palonosetron hydrochloride
43 Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Terminated NCT00012246 Phase 2
44 Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma Unknown status NCT00562068 Phase 1 cyclophosphamide;doxorubicin hydrochloride;prednisolone;vincristine sulfate
45 Irinotecan and Capecitabine in Treating Patients With Solid Tumors Unknown status NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
46 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
47 Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer Completed NCT00019773 Phase 1 capecitabine;oxaliplatin
48 Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma Completed NCT00561418 Phase 1 vorinostat
49 Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma Completed NCT00006009 Phase 1
50 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma Completed NCT00088868 Phase 1 alvespimycin hydrochloride

Search NIH Clinical Center for Small Intestine Cancer

Genetic Tests for Small Intestine Cancer

Genetic tests related to Small Intestine Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Small Intestine 28

Anatomical Context for Small Intestine Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Small Intestine Cancer:

18
The Small Intestine

MalaCards organs/tissues related to Small Intestine Cancer:

38
Small Intestine, Liver, Lung, T Cells, Bone, Breast, Skin

Publications for Small Intestine Cancer

Articles related to Small Intestine Cancer:

# Title Authors Year
1
Hemorrhagic small intestine cancer with solitary pulmonary metastasis initially presented as suspected primary lung cancer: an autopsy report. ( 18432067 )
2007
2
Associations between small intestine cancer and other primary cancers: an international population-based study. ( 16003748 )
2006
3
Small Intestine Cancer Treatment (PDQAr): Health Professional Version ( 26389423 )
2002
4
Small Intestine Cancer Treatment (PDQAr): Health Professional Version ( 26889555 )
2002
5
Small Intestine Cancer Treatment (PDQAr): Patient Version ( 27390834 )
2002
6
Small Intestine Cancer Treatment (PDQAr): Patient Version ( 26389461 )
2002
7
Risk factors for small intestine cancer. ( 8481495 )
1993

Variations for Small Intestine Cancer

Expression for Small Intestine Cancer

Search GEO for disease gene expression data for Small Intestine Cancer.

Pathways for Small Intestine Cancer

GO Terms for Small Intestine Cancer

Cellular components related to Small Intestine Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 8.96 MLH1 MSH2
2 MutSalpha complex GO:0032301 8.62 MSH2 MSH6

Biological processes related to Small Intestine Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.86 CCND1 MLH1 MSH2 MSH6
2 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.71 KRAS MUC2 MUC6
3 response to X-ray GO:0010165 9.55 CCND1 MSH2
4 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.54 MLH1 MSH2 MSH6
5 determination of adult lifespan GO:0008340 9.52 MSH2 MSH6
6 maintenance of gastrointestinal epithelium GO:0030277 9.51 MUC2 MUC6
7 mismatch repair GO:0006298 9.5 MLH1 MSH2 MSH6
8 positive regulation of isotype switching to IgG isotypes GO:0048304 9.49 MLH1 MSH2
9 positive regulation of helicase activity GO:0051096 9.48 MSH2 MSH6
10 negative regulation of DNA recombination GO:0045910 9.46 MSH2 MSH6
11 maintenance of DNA repeat elements GO:0043570 9.43 MSH2 MSH6
12 positive regulation of isotype switching to IgA isotypes GO:0048298 9.4 MLH1 MSH2
13 somatic hypermutation of immunoglobulin genes GO:0016446 9.33 MLH1 MSH2 MSH6
14 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.26 MLH1 MSH2
15 isotype switching GO:0045190 9.13 MLH1 MSH2 MSH6
16 somatic recombination of immunoglobulin gene segments GO:0016447 8.8 MLH1 MSH2 MSH6

Molecular functions related to Small Intestine Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded DNA binding GO:0003690 9.58 CDX2 MSH2 MSH6
2 four-way junction DNA binding GO:0000400 9.43 MSH2 MSH6
3 oxidized purine DNA binding GO:0032357 9.37 MSH2 MSH6
4 MutLalpha complex binding GO:0032405 9.32 MSH2 MSH6
5 single guanine insertion binding GO:0032142 9.26 MSH2 MSH6
6 single thymine insertion binding GO:0032143 9.16 MSH2 MSH6
7 mismatched DNA binding GO:0030983 9.13 MLH1 MSH2 MSH6
8 guanine/thymine mispair binding GO:0032137 8.8 MLH1 MSH2 MSH6

Sources for Small Intestine Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....